eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h30 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs)...
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
09 août 2022 16h01 HE
|
eFFECTOR Therapeutics, Inc.
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chief medical officer SAN DIEGO and REDWOOD...
eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer
08 août 2022 05h30 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”)...
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
07 juin 2022 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation...
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity
05 juin 2022 17h00 HE
|
eFFECTOR Therapeutics, Inc.
Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast cancer...
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting
26 mai 2022 17h15 HE
|
eFFECTOR Therapeutics, Inc.
Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on expanded development of zotatifin in...
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
10 mai 2022 16h02 HE
|
eFFECTOR Therapeutics, Inc.
Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded development of zotatifin SAN DIEGO and REDWOOD CITY,...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
02 mai 2022 16h04 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation...
eFFECTOR Therapeutics Announces Transition in Clinical Leadership
04 avr. 2022 08h30 HE
|
eFFECTOR Therapeutics, Inc.
Premal Patel, M.D., Ph.D., chief medical officer, has resigned to pursue a new career opportunity Robert Sikorski, M.D., Ph.D., to take on expanded role as senior clinical development advisor SAN...
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
16 mars 2022 16h01 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs)...